InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Friday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Performance

Shares of InspireMD stock opened at $2.45 on Friday. The firm has a fifty day moving average of $2.69 and a two-hundred day moving average of $2.56. The stock has a market capitalization of $61.08 million, a price-to-earnings ratio of -3.31 and a beta of 0.91. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.77.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the firm posted ($0.24) EPS. As a group, research analysts forecast that InspireMD will post -0.82 EPS for the current fiscal year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.